Syndax Pharmaceuticals (NASDAQ:SNDX) Sets New 52-Week Low – Should You Sell?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)’s stock price reached a new 52-week low during mid-day trading on Wednesday. The stock traded as low as $12.69 and last traded at $12.72, with a volume of 1,656,243 shares trading hands. The stock had previously closed at $14.29.

Syndax Pharmaceuticals News Roundup

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: Syndax is set to feature 19 drug abstracts at the American Society of Hematology (ASH) 2026 meeting. The breadth of presentations could raise investor interest in its pipeline, though the supplied reports do not detail the data or establish how clinically meaningful it will be. Syndax Pharmaceuticals stock: ASH to feature 19 drug abstracts Why Is Syndax Pharmaceuticals (SNDX) Drawing So Much ASH 2026 Attention?
• Positive Sentiment: A Seeking Alpha analysis points to strong commercial growth for Revuforj, supporting the investment case. It also identifies frontline AML as a key test for the company, making future clinical and commercial progress important to the outlook. Syndax Pharmaceuticals: Revuforj Shows Strong Commercial Growth, But Frontline AML Is The Key
• Neutral Sentiment: HC Wainwright maintained a Buy rating and a $36 price target. Its forecast updates were mixed, including a small improvement for 2026 and higher 2029–2030 estimates, but these are analyst projections rather than company guidance.
• Neutral Sentiment: Syndax reported inducement equity grants to new employees, a routine hiring-related disclosure that may have a modest dilutive effect. Syndax Pharmaceuticals Reports Inducement Grants
• Negative Sentiment: Pomerantz LLP said it is investigating potential claims on behalf of Syndax investors. The announcement could add uncertainty, but it is an investigation—not a finding of wrongdoing—and the notice provided no further detail on the claims. Pomerantz investor alert
• Negative Sentiment: HC Wainwright lowered its 2027 EPS estimate from a smaller loss to a larger loss and cut its 2028 forecast from a profit to a loss, signaling a weaker expected earnings path in those years.

Wall Street Analyst Weigh In

SNDX has been the subject of several research analyst reports. UBS Group reiterated a “buy” rating on shares of Syndax Pharmaceuticals in a research note on Thursday, October 1st. Weiss Ratings upgraded Syndax Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. HC Wainwright cut their price target on Syndax Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating for the company in a report on Tuesday. JPMorgan Chase & Co. reduced their price objective on shares of Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $35.00 price objective on shares of Syndax Pharmaceuticals in a report on Tuesday, September 29th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $41.60.

Syndax Pharmaceuticals Stock Performance

The company has a market cap of $858.89 million, a P/E ratio of -4.04 and a beta of 0.48. The company has a quick ratio of 6.44, a current ratio of 4.69 and a debt-to-equity ratio of 38.95. The stock has a 50 day moving average price of $16.54 and a two-hundred day moving average price of $20.07.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings results on Monday, November 2nd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.05). The firm had revenue of $83.30 million during the quarter, compared to the consensus estimate of $81.38 million. Syndax Pharmaceuticals had a negative net margin of 72.32% and a negative return on equity of 804.38%. The business’s revenue for the quarter was up 81.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.70) earnings per share. On average, research analysts predict that Syndax Pharmaceuticals, Inc. will post -2.08 earnings per share for the current fiscal year.

Insider Activity at Syndax Pharmaceuticals

In related news, Director Dennis Podlesak sold 8,000 shares of the company’s stock in a transaction dated Thursday, October 29th. The shares were sold at an average price of $14.21, for a total value of $113,680.00. Following the transaction, the director directly owned 239,763 shares in the company, valued at approximately $3,407,032.23. This represents a 3.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in SNDX. BlackRock Inc. bought a new position in Syndax Pharmaceuticals in the second quarter valued at about $197,177,000. Bank of America Corp DE bought a new position in shares of Syndax Pharmaceuticals in the second quarter worth about $88,426,000. Elmind Capital LP bought a new position in shares of Syndax Pharmaceuticals in the second quarter worth about $40,550,300. Trails Edge Capital Partners LP acquired a new stake in shares of Syndax Pharmaceuticals in the 2nd quarter valued at approximately $24,264,600. Finally, Algert Global LLC boosted its stake in shares of Syndax Pharmaceuticals by 13.2% in the 2nd quarter. Algert Global LLC now owns 1,051,465 shares of the company’s stock valued at $22,985,000 after purchasing an additional 122,897 shares in the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc (NASDAQ:SNDX) is a biopharmaceutical company focused on developing and commercializing therapies for cancer and immune-related diseases. Founded in 2005 and headquartered in Waltham, Massachusetts, the company develops medicines designed to address genetically defined cancers and serious complications associated with cancer treatment.

Syndax’s lead product is Revuforj (revumenib), an oral menin inhibitor approved in the United States for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in eligible adults and children.